Ebola virus disease (EVD), Ebola hemorrhagic fever (EHF), or simply Ebola is a disease of humans and other primates caused by the ebolavirus. The virus may be acquired upon contact with blood or bodily fluids of an infected animal. No specific treatment for the disease is yet available. The disease has a high risk of death, killing between 50% and 90% of those infected with the virus. The largest outbreak to date is the ongoing 2014 West African Ebola outbreak, which is affecting Guinea, Sierra Leone, Liberia and Nigeria.
Dr. M. Javad Aman, received his Ph.D. in molecular immunology at the University of Mainz, Germany. Following a research fellowship at the National Institute of Health and an academic position at the University of Virginia, he worked as a lead scientist at USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases) for seven years prior to founding Integrated BioTherapeutics (IBT). His research at USAMRIID resulted in the development of a vaccine for Ebola and Marburg viruses, now in late pre-clinical development. His work has also led to small molecule inhibitors of filoviruses currently in development by Functional Genetics Inc. under a DTRA (Defense Threat Reduction Agency) funded program, as well as human therapeutic antibodies for Staphylococcal Enterotoxin B, currently funded by NIAID and under development at IBT. Dr. Aman is currently the President and Chief Scientific Officer at IBT and serves as the principle investigator on multiple government funded contracts and grants. He has authored over 60 publications in international journals and is the inventor on multiple U.S. and international patents and patent applications.
Located in Gaithersburg, Maryland, Integrated BioTherapeutics, Inc. (IBT) is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases. IBT’s pipeline includes promising product candidates for several bacterial and viral infections. The bacterial program is focused on development of a multivalent vaccine for staphylococcal infections primarily by targeting a variety of toxins produced by S. aureus. IBT’s antiviral pipeline includes candidate vaccines and antibody therapeutics for Hepatitis C Virus and viral hemorrhagic fevers caused by the deadly Ebola and Marburg viruses.
Dr. M. Javad Aman
“Fighting the Ebola Beast: the Race between a Big Virus and Little Antibodies”
1PM in Mainz, Germany
Lecture Hall, Building 708
University Medical Center Mainz